Ki67 as a Prognostic and Predictive Biomarker in HR-Positive/HER2-Negative Early Breast Cancer 

This 60-minute interactive webinar will feature the expertise of a pathologist and an oncologist highlighting important and practice-changing developments related to the use of Ki67 biomarker testing in patients with HR-positive/HER2-negative early breast cancer, such as new clinical data with immediate implications for patient care. Case-based, and with expert perspectives and recommendations, this webinar addresses key educational gaps and controversies related to optimal Ki67 biomarker testing methods, including challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.  

Topics covered will include: 

• Analytical validity of Ki67 as a diagnostic assay, application of results in clinical practice, and relevance to therapy 

• Current and emerging therapies for HR-positive/HER2-negative early-stage breast cancer 

• Current standardized methodologies for Ki67 quantification 

• Optimizing workflows and communications with the multidisciplinary team 

The activity offers 1.0 CME/CMLE credit. 

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. 

Faculty/Authors

Sunil S. Badve, MD, FRCPath
Vice Chair, Pathology Cancer Programs, Department of Pathology and Laboratory Medicine
Emory University School of Medicine
Atlanta, GA 

Manali Bhave, MD
Assistant Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA 

Physician's Competency: Patient care, Medical knowledge, Interpersonal and Communication Skills, Professionalism   

CME/CMLE Credit: 1.0
Estimated Completion Time: 1.0 hour
Format: Online educational activity

Credit Designation Statement

Method of Participation

To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided online. 

Provided by the American Society for Clinical Pathology in partnership with Clinical Care Options, LLC 

This activity is supported by an educational grant from Lilly. 

Instructions

To claim CME/CMLE credit for the exercise, do the following:

1. Review the Technical Considerations.
2. Click Go to Content and click the first module of the course.
3. Complete the Demographic Survey.
4. Review the Educational Activity.
5. Submit the Post-Activity Survey.
6. Submit the course Evaluation.
7. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Upon completion of this activity, you will be able to:

• Incorporate the evidence on the current use of Ki67 as a predictive and prognostic biomarker into clinical practice 

• Evaluate the clinical validity, utility, and differences among Ki67 assessment techniques 

• Integrate best practices for Ki67 testing methodology, standardization, and reporting 

• Identify patients with high-risk features who may benefit from the addition of CDK4/6 inhibitor therapy to endocrine therapy in the adjuvant setting 

• Foster collaborative discussions and workflows between oncologists, pathologists and the multidisciplinary team on recent clinical evidence to guide personalized treatment planning for HR-positive/HER2-negative early breast cancer 

• Identify patients with HR-positive/HER2-negative early breast cancer that expresses Ki67 who may be eligible for ongoing clinical trials